Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - Analyses of cases from two prospective randomized clinical trials

Haematologica

Volumn 94, Issue 11, 2009, Pages 1569-1580

  Bernd, Heinz Wolfram ^a   Ziepert, Marita ^b   Thorns, Christoph ^a   Klapper, Wolfram ^c   Wacker, Hans Heinrich ^c   Hummel, Michael ^d   Stein, Harald ^d   Hansmann, Martin Leo ^e   Ott, German ^f,l   Rosenwald, Andreas ^f   Müller Hermelink, Hans Konrad ^f   Barth, Thomas F E ^g   Möller, Peter ^g   Cogliatti, Sergio B ^h   Pfreundschuh, Michael ⁱ   Schmitz, Norbert ^j   Trümper, Lorenz ^k   Höller, Silvia ^f,m   Löffler, Markus ^b   Feller, Alfred C ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ SAARLAND UNIVERSITY   (Germany)

^j DEPARTMENT OF CARDIOLOGY   (Germany)

^k UNIVERSITY OF GÖTTINGEN   (Germany)

^l ROBERT BOSCH HOSPITAL   (Germany)

^m UNIVERSITY OF BASEL   (Switzerland)

more..

Author keywords

Diffuse large B cell lymphoma; HLA DR; Immunoblastic lymphoma; Prognosis

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HLA DR ANTIGEN; INTERFERON REGULATORY FACTOR 4; PREDNISOLONE; PROTEIN BCL 6; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CELL STRUCTURE; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; FOLLICULAR DENDRITIC CELL; HUMAN; HUMAN TISSUE; IMMUNOBLAST; IMMUNOHISTOCHEMISTRY; INTERRATER RELIABILITY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PROGNOSIS; TISSUE MICROARRAY;

EID: 70449365381     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.008862     Document Type: Article

References (58)

1. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive NHL: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987.
2. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74. (Pubitemid 34101731)
3. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511 (Pubitemid 30082188)
4. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947
5. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282 (Pubitemid 38029949)
6. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, et al. German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-641
7. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. German High-Grade Non- Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-633
8. Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 2007; 13:6666-6672 (Pubitemid 350206802)
9. Miller TP, Lippman SM, Spier CM, Slymen DJ, Grogan TM. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 1988;82:370-372
10. Rybski JA, Spier CM, Miller TP, et al. Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class I (HLA-A, -B, -C) and class II (HLADR, -DP, -DQ) phenotype. Leuk Lymphoma 1991;6:31-38
11. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004;103:4251-4258 (Pubitemid 38685371)
12. Rimsza LM, Farinha P, Fuchs DA, Masoudi H, Connors JM, Gascoyne RD. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma 2007;48:542-546 (Pubitemid 46487763)
13. Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78-84. (Pubitemid 36025890)
14. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, et al. Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244-251 (Pubitemid 27276568)
15. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996;7:265-272
16. Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak HL, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996;14:2131-2138 (Pubitemid 26230116)
17. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France 2001;171-174
18. Stocker K, Stocker W, Ritter-Frank Y, Scriba PC. Chemically activated glass slides for frozen sections and their use in autoantibody diagnosis. Acta Histochem 1985; Suppl 31: 283-294
19. Stocker W. Rational histochemistry using a new microanalytic technic. Acta Histochem 1985; (Suppl 31): 269-281
20. Feller AC, Wacker HH, Moldenhauer G, Radzun HJ, Parwaresch MR. Monoclonal antibody Ki-B3 detects a formalin resistant antigen on normal and neoplastic B cells. Blood 1987;70:629-636 (Pubitemid 18027391)
21. HLDA Database at: http://www99. mh-hannover.de/aktuelles/projekte/ hlda7/hldabase/select.htm
22. Hansmann ML, Wacker HH, Gralla J, Lumbeck H, Kossmahl M, Heidebrecht HJ, et al. Ki-B5: a monoclonal antibody unrelated to CD45 recognizes normal and neoplastic human B cells in routine paraffin sections. Blood 1991;77: 809-817
23. Chadburn A, Husain S, Knowles DM. Monoclonal antibody OPD4 detects neoplastic T cells but does not distinguish between CD4 and CD8 neoplastic T cells in paraffin tissue sections. Hum Pathol 1992;23:940-947
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958;53:457-481.
25. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464-470 (Pubitemid 38436519)
26. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005;18:1113-1120 (Pubitemid 41224503)
27. Haarer CF, Roberts RA, Frutiger YM, Grogan TM, Rimsza LM. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med 2006;130:1819-1824
28. De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005;23:7060-7068 (Pubitemid 46260293)
29. Veelken H, Vik Dannheim S, Schulte Moenting J, Martens UM, Finke J, Schmitt-Graeff A. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol 2007;18:931-939 (Pubitemid 47054092)
30. de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, et al. Lunenburg Lymphoma Biomarker Consortium. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805-812 (Pubitemid 350002880)
31. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419-2430
32. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991-9996 (Pubitemid 37087056)
33. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323
34. Möller P, Herrmann B, Moldenhauer G, Momburg F. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Int J Cancer 1987;40:32-39 (Pubitemid 17099966)
35. Momburg F, Herrmann B, Moldenhauer G, Moller P. B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and - DQ antigens and associated invariant chain. Int J Cancer 1987;40:598-603. (Pubitemid 18003845)
36. Issekutz T, Chu E, Geha RS. Antigen presentation by human B cells: T cell proliferation induced by Epstein Barr virus B lymphoblastoid cells. J Immunol 1982;129:1446-1450 (Pubitemid 12031069)
37. Santoli D, Radka SF, Igarashi M, Kreider BL, Ferrone S. Autologous B lymphoblastoid cell lines and longterm cultured T cells as stimulators in the mixed lymphocyte reaction: analysis of the role of HLA class II antigens as stimulatory molecules. J Immunol 1986;137:400-407 (Pubitemid 16045058)
38. Stopeck AT, Gessner A, Miller TP, Hersh EM, Johnson CS, Cui H, et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 2000;6:3904-3909 (Pubitemid 30807081)
39. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425-3433
40. Riemersma SA, Jordanova ES, Schop RF. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immuneprivileged sites. Blood 2000; 96:3569-3577
41. van Imhoff GW, Boerma EJ, van der Holt B, Schuuring E, Verdonck LF, Kluin-Nelemans HC, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24:4135-4142 (Pubitemid 46622290)
42. Warnke R, Miller R, Grogan T, Pederson M, Dilley J, Levy R. Immunologic phenotype in 30 patients with diffuse large-cell lymphoma. N Engl J Med 1980;303:293-300. (Pubitemid 10040016)
43. Horning SJ, Doggett RS, Warnke RA, Dorfman RF, Cox RS, Levy R. Clinical relevance of immunologic phenotype in diffuse large cell lymphoma. Blood 1984;63:1209-1215
44. [No authors listed] National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49:2112-2135
45. Brittinger G, Bartels H, Common H, Duhmke E, Fulle HH, Gunzer U, et al. Clinical and prognostic relevance of the Kiel classification of non- Hodgkin lymphomas: results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 1984;2:269-306. (Pubitemid 14044531)
46. Engelhard M, Brittinger G, Huhn D, Gerhartz HH, Meusers P, Siegert W, et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997;89:2291-2297 (Pubitemid 27143274)
47. Vago JF, Weisenburger DD, Armitage JO. Do pathologic features predict prognosis in diffuse large B-cell lymphoma? Hematol Pathol 1987;1:217-225
48. Nathwani BN, Dixon DO, Jones SE, Hartsock RJ, Rebuck JW, Byrne GE Jr, et al. The clinical significance of the morphological subdivision of diffuse "histocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group. Blood 1982;60:1068-1074
49. Diebold J, Anderson JR, Armitage JO, Connors JM, Maclennan KA, Muller-Hermelink HK, et al. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma 2002;43:97-104. (Pubitemid 34223976)
50. Kwak LW, Wilson M, Weiss LM, Horning SJ, Warnke RA, Dorfman RF. Clinical significance of morphologic subdivision in diffuse large cell lymphoma. Cancer 1991;68:1988-1993
51. Camara DA, Stefanoff CG, Pires AR, Soares F, Biasoli I, Zalcberg I, et al. Immunoblastic morphology in diffuse large B-cell lymphoma is associated with a nongerminal center immunophenotypic profile. Leuk Lymphoma 2007;48:892-896 (Pubitemid 47161560)
52. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392 (Pubitemid 24273002)
53. Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, Zehnder JL, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001;98:945-951
54. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6387- 93.
55. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ Bcell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116
56. Nyman H, Adde M, Karjalainen- Lindsberg ML, Taskinen M, Berglund M, Amini RM, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930-4935 (Pubitemid 46827791)
57. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-4213 (Pubitemid 43801342)
58. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-4284